CD8A and neoplasm: Interestingly, the therapeutic effects of combination treatment combining CCL2 antagonist and anti-programmed death-ligand 1 antibody in lung tumor-bearing mice decreased MDSC in the periphery and tumor through an enhanced CD4+ and CD8+ T lymphocyte infiltration and increased the survival time compared to single agent alone [110].